Marinus Pharmaceuticals, Inc.’s Ztalmy (ganaxolone) won European Commission approval in July 2023 as an oral treatment for seizures associated with a rare, genetic pediatric-onset epilepsy disorder. The drug was previously approved by the US FDA in March 2022, which marked an important moment for the company, as the drug had previously failed in clinical trials for Fragile X syndrome and post-partum depression.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?